{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:02:10Z","timestamp":1768312930056,"version":"3.49.0"},"reference-count":37,"publisher":"Tohoku University Medical Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1620\/tjem.2023.j033","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T22:12:45Z","timestamp":1681942365000},"page":"263-271","source":"Crossref","is-referenced-by-count":6,"title":["Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-<i>\u03b1<\/i> Blocking Therapy in Patients with Ankylosing Spondylitis"],"prefix":"10.1620","volume":"260","author":[{"given":"Yulan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, the First People\u2019s Hospital of Linping District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, the First People\u2019s Hospital of Linping District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, the First People\u2019s Hospital of Linping District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunchu","family":"Yu","sequence":"additional","affiliation":[{"name":"Obstetrical Department, the First People\u2019s Hospital of Linping District"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Acurcio, F.A., Guerra Junior, A.A., da Silva, M.R.R., Pereira, R.G., Godman, B., Bennie, M., Nedjar, H. & Rahme, E. (2020) Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Curr. Med. Res. Opin.<\/i>, 36, 677-686.","DOI":"10.1080\/03007995.2020.1722945"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Davidson, S., Crotta, S., McCabe, T.M. & Wack, A. (2014) Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun.<\/i>, 5, 3864.","DOI":"10.1038\/ncomms4864"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Feng, Y., Ding, J., Fan, C.M. & Zhu, P. (2012) Interferon-gamma contributes to HLA-B27-associated unfolded protein response in spondyloarthropathies. J. Rheumatol.<\/i>, 39, 574-582.","DOI":"10.3899\/jrheum.101257"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Grubisic, F., Naglic, D.B., Peric, P., Morovic-Vergles, J., Anic, B., Kehler, T., Novak, S., Hanih, M., Gracanin, A.G., Markovic, N.L. & Grazio, S. (2022) Clinical efficacy and safety of adalimumab versus etanercept in patients with ankylosing spondylitis and total spinal ankylosis in Croatia: a multicentre 12-month follow-up study. Clin. Rheumatol.<\/i>, 41, 2417-2421.","DOI":"10.1007\/s10067-022-06177-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Harrison, S.R., Burska, A.N., Emery, P., Marzo-Ortega, H. & Ponchel, F. (2021) Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. Rheumatology <\/i>(Oxford<\/i>), 60, 3607-3616.","DOI":"10.1093\/rheumatology\/keaa817"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Ivashkiv, L.B. & Donlin, L.T. (2014) Regulation of type I interferon responses. Nat. Rev. Immunol.<\/i>, 14, 36-49.","DOI":"10.1038\/nri3581"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Klasen, C., Meyer, A., Wittekind, P.S., Waque, I., Nabhani, S. & Kofler, D.M. (2019) Prostaglandin receptor EP4 expression by Th17 cells is associated with high disease activity in ankylosing spondylitis. Arthritis Res. Ther.<\/i>, 21, 159.","DOI":"10.1186\/s13075-019-1948-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Klavdianou, K., Tsiami, S. & Baraliakos, X. (2021) New developments in ankylosing spondylitis-status in 2021. Rheumatology <\/i>(Oxford<\/i>), 60, vi29-vi37.","DOI":"10.1093\/rheumatology\/keab523"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Lee, S.H., Kim, Y.G., Lee, S.G., Lee, S.H., Kim, Y.J., Jeon, J.Y., Jo, J.Y., Yoo, H.J., Lee, J. & Kim, T.H. (2022a) Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: a multicenter cross-sectional observational study. Int. J. Rheum. Dis.<\/i>, 25, 523-531.","DOI":"10.1111\/1756-185X.14304"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Lee, T.H., Koo, B.S., Nam, B., Kim, Y.J., Son, D., Lee, S., Joo, K.B. & Kim, T.H. (2022b) Age-stratified trends in the progression of spinal radiographic damage in patients with ankylosing spondylitis: a longitudinal study. Ther. Adv. Musculoskelet. Dis.<\/i>, 14, 1759720X221100301.","DOI":"10.1177\/1759720X221100301"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Lie, E., Lindstrom, U., Zverkova-Sandstrom, T., Olsen, I.C., Forsblad-d\u2019Elia, H., Askling, J., Kapetanovic, M.C., Kristensen, L.E. & Jacobsson, L.T.H. (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann. Rheum. Dis.<\/i>, 76, 1515-1521.","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lu, X., Tang, Q., Lindh, M., Dastmalchi, M., Alexanderson, H., Popovic Silwerfeldt, K., Agerberth, B., Lundberg, I.E. & Wick, C. (2017) The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. J. Autoimmun.<\/i>, 78, 46-56.","DOI":"10.1016\/j.jaut.2016.12.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Manivasagam, S. & Klein, R.S. (2021) Type III interferons: emerging roles in autoimmunity. Front. Immunol.<\/i>, 12, 764062.","DOI":"10.3389\/fimmu.2021.764062"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Mauro, D., Thomas, R., Guggino, G., Lories, R., Brown, M.A. & Ciccia, F. (2021) Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat. Rev. Rheumatol.<\/i>, 17, 387-404.","DOI":"10.1038\/s41584-021-00625-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O\u2019Garra, A. (2015) Type I interferons in infectious disease. Nat. Rev. Immunol.<\/i>, 15, 87-103.","DOI":"10.1038\/nri3787"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Navid, F., Holt, V. & Colbert, R.A. (2021) The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. Semin. Immunopathol.<\/i>, 43, 235-243.","DOI":"10.1007\/s00281-021-00838-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Nezos, A., Gravani, F., Tassidou, A., Kapsogeorgou, E.K., Voulgarelis, M., Koutsilieris, M., Crow, M.K. & Mavragani, C.P. (2015) Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis. J. Autoimmun.<\/i>, 63, 47-58.","DOI":"10.1016\/j.jaut.2015.07.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Oke, V., Gunnarsson, I., Dorschner, J., Eketjall, S., Zickert, A., Niewold, T.B. & Svenungsson, E. (2019) High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res. Ther.<\/i>, 21, 107.","DOI":"10.1186\/s13075-019-1878-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ornbjerg, L.M., Brahe, C.H., Askling, J., Ciurea, A., Mann, H., Onen, F., Kristianslund, E.K., Nordstrom, D., Santos, M.J., Codreanu, C., Gomez-Reino, J., Rotar, Z., Gudbjornsson, B., Di Giuseppe, D., Nissen, M.J., et al. (2019) Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann. Rheum. Dis.<\/i>, 78, 1536-1544.","DOI":"10.1136\/annrheumdis-2019-215427"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Ornbjerg, L.M., Linde, L., Georgiadis, S., Rasmussen, S.H., Lindstrom, U., Askling, J., Michelsen, B., Giuseppe, D.D., Wallman, J.K., Pavelka, K., Zavada, J., Nissen, M.J., Jones, G.T., Relas, H., Pirila, L., et al. (2022) Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration. Semin. Arthritis Rheum.<\/i>, 56, 152081.","DOI":"10.1016\/j.semarthrit.2022.152081"},{"key":"21","unstructured":"Pollard, K.M., Cauvi, D.M., Toomey, C.B., Morris, K.V. & Kono, D.H. (2013) Interferon-gamma and systemic autoimmunity. Discov. Med.<\/i>, 16, 123-131."},{"key":"22","doi-asserted-by":"crossref","unstructured":"Postal, M., Vivaldo, J.F., Fernandez-Ruiz, R., Paredes, J.L., Appenzeller, S. & Niewold, T.B. (2020) Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol.<\/i>, 67, 87-94.","DOI":"10.1016\/j.coi.2020.10.014"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Proft, F. & Poddubnyy, D. (2018) Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther. Adv. Musculoskelet. Dis.<\/i>, 10, 129-139.","DOI":"10.1177\/1759720X18773726"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Raychaudhuri, S.P. & Raychaudhuri, S.K. (2016) IL-23\/IL-17 axis in spondyloarthritis-bench to bedside. Clin. Rheumatol.<\/i>, 35, 1437-1441.","DOI":"10.1007\/s10067-016-3263-4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Reder, A.T. & Feng, X. (2014) How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J. Interferon Cytokine Res.<\/i>, 34, 589-599.","DOI":"10.1089\/jir.2013.0158"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Ritchlin, C. & Adamopoulos, I.E. (2021) Axial spondyloarthritis: new advances in diagnosis and management. BMJ<\/i>, 372, m4447.","DOI":"10.1136\/bmj.m4447"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Robinson, P.C., van der Linden, S., Khan, M.A. & Taylor, W.J. (2021) Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat. Rev. Rheumatol.<\/i>, 17, 109-118.","DOI":"10.1038\/s41584-020-00552-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Rodriguez-Carrio, J., Lopez, P. & Suarez, A. (2015) Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. Clin. Sci. <\/i>(Lond.<\/i>), 128, 449-464.","DOI":"10.1042\/CS20140554"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Skaug, B. & Assassi, S. (2020) Type I interferon dysregulation in Systemic Sclerosis. Cytokine<\/i>, 132, 154635.","DOI":"10.1016\/j.cyto.2018.12.018"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Tahir, H. (2018) Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology <\/i>(Oxford<\/i>), 57, vi23-vi28.","DOI":"10.1093\/rheumatology\/key152"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Thurlings, R.M., Boumans, M., Tekstra, J., van Roon, J.A., Vos, K., van Westing, D.M., van Baarsen, L.G., Bos, C., Kirou, K.A., Gerlag, D.M., Crow, M.K., Bijlsma, J.W., Verweij, C.L. & Tak, P.P. (2010) Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum.<\/i>, 62, 3607-3614.","DOI":"10.1002\/art.27702"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Voruganti, A. & Bowness, P. (2020) New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology<\/i>, 161, 94-102.","DOI":"10.1111\/imm.13242"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Walsh, J.A., Adejoro, O., Chastek, B. & Park, Y. (2018) Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J. Comp. Eff. Res.<\/i>, 7, 369-380.","DOI":"10.2217\/cer-2017-0076"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Walter, M.R. (2020) The role of structure in the biology of interferon signaling. Front. Immunol.<\/i>, 11, 606489.","DOI":"10.3389\/fimmu.2020.606489"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhao, Q., Wang, G., Yang, C., Xu, Y., Li, Y. & Yang, P. (2016) Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis. Cytokine<\/i>, 81, 10-14.","DOI":"10.1016\/j.cyto.2016.01.012"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Webers, C., Ortolan, A., Sepriano, A., Falzon, L., Baraliakos, X., Landewe, R.B.M., Ramiro, S., van der Heijde, D. & Nikiphorou, E. (2023) Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann. Rheum. Dis.<\/i>, 82, 130-141.","DOI":"10.1136\/ard-2022-223298"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zhang, S., Peng, L., Li, Q., Zhao, J., Xu, D., Zhao, J., Wang, Q., Li, M., Zhang, W., Tian, X., Su, J. & Zeng, X. (2022) Spectrum of spondyloarthritis among Chinese populations. Curr. Rheumatol. Rep.<\/i>, 24, 247-258.","DOI":"10.1007\/s11926-022-01079-1"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/3\/260_2023.J033\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T04:53:40Z","timestamp":1689396820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/3\/260_2023.J033\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2023.j033","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2023.J033"}}